Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Drug ineffective, SARS-CoV-2 test, Sinusitis
Clinical narrative: Patient tested covid positive in october of 2021; cough; sinus infection; lack of drug effect; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Patient tested covid positive in october of 2021), COUGH (cough), SINUSITIS (sinus infection) and DRUG INEFFECTIVE (lack of drug effect) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 028A21A) for COVID-19 vaccination.     The patient's past medical history included Cancer (Patient reported having cancer 20 years ago). Concurrent medical conditions included Hypertension.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2021, the patient experienced COVID-19 (Patient tested covid positive in october of 2021), COUGH (cough), SINUSITIS (sinus infection) and DRUG INEFFECTIVE (lack of drug effect). The patient was treated with ERYTHROMYCIN for Sinus infection, at an unspecified dose and frequency. At the time of the report, COVID-19 (Patient tested covid positive in october of 2021), COUGH (cough), SINUSITIS (sinus infection) and DRUG INEFFECTIVE (lack of drug effect) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In October 2021, SARS-CoV-2 test: positive (Positive) Positive.         Concomitant medication information was not provided by the reporter. Treatment information also included steroids to treat sinus condition.  Company comment: This case concerns a male patient, with reported medical history of Hypertension, who experienced the non-serious AESI of COVID-19. Additionally, Drug ineffective was also reported. The events were reported to occur approximately 6 months after the administration of the second dose of a proper schedule of vaccination with the mRNA-1273 vaccine (33 days between doses).  Further information received states that the patient required treatment with steroids and Erythromycin due to a concomitant sinus condition.  The rechallenge is not applicable as the events occurred after the administration of the second dose of the mRNA-1273 vaccine.  Reported medical history of Hypertension remains as a contributing factor for the event COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a male patient, with reported medical history of Hypertension, who experienced the non-serious AESI of COVID-19. Additionally, Drug ineffective was also reported. The events were reported to occur approximately 6 months after the administration of the second dose of a proper schedule of vaccination with the mRNA-1273 vaccine (33 days between doses).  Further information received states that the patient required treatment with steroids and Erythromycin due to a concomitant sinus condition.  The rechallenge is not applicable as the events occurred after the administration of the second dose of the mRNA-1273 vaccine.  Reported medical history of Hypertension remains as a contributing factor for the event COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.